Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Omberacetam (Noopept)
Beginner tier: 10 mg, daily · 8w on / 4w off · clinical trials
Also known as: Noopept, GVS-111, omberacetam
Roughly 1,000 times more potent than piracetam by weight, at doses measured in milligrams instead of grams. Omberacetam (Noopept, GVS-111) is a synthetic dipeptide nootropic approved in Russia for mild cognitive disorders. Neznamov and Teleshova's 2009 RCT [1] showed it outperformed piracetam on Mini-Mental State scores across a 56-day course at just 20 mg per day. BDNF and NGF expression climbs with sustained use rather than fading, which is unusual for a cognitive compound. More than 500 Reddit threads track real-world experience across r/Nootropics. No Western clinical trials exist, and the longest human study ran eight weeks.
What Is Omberacetam (Noopept)?
Does a 10 mg tablet really outperform 1,200 mg of piracetam? The 2009 Neznamov and Teleshova RCT [1] confirmed it did, producing superior MMSE improvements over 56 days in patients with mild cognitive disorders.
Omberacetam (also sold as Noopept, chemical name N-phenylacetyl-L-prolylglycine ethyl ester, CAS 157115-85-0, designated GVS-111) is a synthetic dipeptide developed in Russia by the Zakusov Institute. After oral dosing, liver esterases rapidly convert it to cycloprolylglycine (CPG), the active metabolite with a seven-hour half-life that does most of the pharmacological work. CPG modulates both AMPA and NMDA glutamate receptors, boosting long-term potentiation in hippocampal circuits.
The mechanism that separates omberacetam from older racetams is neurotrophin upregulation. Ostrovskaya's group confirmed BDNF and NGF increases in rat hippocampus [2]. That signal doesn't fade; expression continues rising with chronic dosing through day 56.
Tens of thousands of users across r/Nootropics and Longecity forums report improved verbal fluency, memory recall, and a calmer quality of thought. The community figured out the choline problem before the researchers did. Without Alpha-GPC or CDP-choline, headaches are nearly guaranteed.
Russia's Generium pharmaceutical company holds market authorization for 10 mg tablets. No Western regulatory body has approved or reviewed omberacetam. All published clinical data comes from Russian institutions with developer involvement.
How Omberacetam (Noopept) Works
After you swallow a 10 mg tablet, omberacetam hits peak plasma in about 15 minutes. It doesn't stay intact for long. Liver esterases cleave it into cycloprolylglycine (CPG), which carries a half-life of roughly seven hours and handles the sustained pharmacology.
CPG binds to the glycine site on NMDA receptors and simultaneously modulates AMPA receptor trafficking. Both actions boost long-term potentiation, the molecular basis of memory formation in the hippocampus. The AMPA component speeds information processing; the NMDA component deepens encoding.
Neurotrophin upregulation is the second pathway. Ostrovskaya's group [2] tracked BDNF and NGF expression in rat hippocampus during chronic dosing. Both growth factors increased progressively rather than plateauing. BDNF supports synaptic remodeling. NGF promotes cholinergic neuron survival, which is why omberacetam drains acetylcholine reserves and causes headaches without choline supplementation.
A third mechanism runs through HIF-1 alpha activation. This transcription factor drives neuroprotective gene expression under oxidative stress. Pelsman's group [3] confirmed omberacetam blocked apoptosis in both normal and Down syndrome human cortical neurons exposed to oxidative challenge.
The parent compound also inhibits calcium-mediated excitotoxicity and suppresses inflammatory cytokine release in CNS tissue [4]. Unlike piracetam, omberacetam achieves all of this at milligram doses because its lipophilicity gets it across the blood-brain barrier fast.
Omberacetam (Noopept) Benefits
- Omberacetam benefits center on memory, neuroprotection, and cognitive clarity at remarkably low doses.
- Outperformed piracetam head-to-head on MMSE scores in Neznamov and Teleshova's 56-day RCT [1], at doses roughly 1,000x smaller by weight.
- BDNF and NGF expression increases progressively with sustained dosing [2]. No plateau through day 56 in rat hippocampus.
- Neuroprotection against amyloid-beta toxicity confirmed in cell models [5]. Reduces tau hyperphosphorylation and blocks apoptotic signaling.
- Users across 500+ Reddit threads consistently report faster verbal fluency and word retrieval within 15 to 30 minutes of sublingual dosing.
- The NA-831 Phase 2A trial (n=112, PMC11712949) tested CPG, the active metabolite, in Alzheimer's patients. The result: a 4.1-point ADAS-Cog-13 improvement over placebo. Conference-abstract level data only.
- Mild anxiolytic effect without sedation, particularly at the 10 mg dose. Community reports describe reduced emotional reactivity under cognitive load.
Omberacetam (Noopept): Science vs Community Consensus
Improves memory, attention, and emotional stability in mild cognitive disorders at 20–30 mg/day over 56-day courses.
Read the evidence (key study, limitations)
BDNF/NGF upregulation confirmed in animal and clinical models. Active metabolite CPG (cycloprolylglycine) may be primary effector: NA-831 Phase 2A AD trial (n=112) showed 4.1-point ADAS-Cog-13 improvement vs. placebo.
Neznamov & Teleshova 2009 (PMID 19234797): RCT vs. piracetam in mild cognitive disorders, 20 mg/day × 56 days, superior MMSE improvement. Ostrovskaya et al. 2008 (PMID 19240853): BDNF/NGF upregulation confirmed in rat hippocampus. NA-831 Phase 2A (PMC11712949): CPG prodrug, 4.1-point ADAS-Cog-13 improvement in 112 AD patients: conference-abstract level only, not full peer-reviewed publication.
All pivotal trials conducted in Russia by original developers: not independently replicated in Western trials. Longest human study = 56 days. No large-scale RCTs in healthy adults. NA-831 Phase 2A data is conference-abstract level only. No new human clinical trials published 2024–2026 (only structural/analytical chemistry paper: Araj et al. 2025, PMID 39298839).
Widely used and generally well-regarded nootropic in r/Nootropics.
Read the reports (what users report 5, common issues 6)
Most valued for rapid-onset verbal fluency, memory consolidation, and mild anxiolytic effect. Choline headache without co-supplementation is the dominant complaint. Highly variable individual response noted.
- Rapid-onset verbal fluency and word retrieval within 15–30 min (sublingual onset ~5 min)
- Improved memory consolidation and episodic recall, especially useful for studying
- Mild anxiolytic and mood-stabilizing effect at low doses (10 mg)
- Faster reading comprehension and information processing speed
- Reduced brain fog under cognitive load
- Headaches without choline co-supplementation: #1 reported community complaint
- Paradoxical brain fog or mental haziness at higher single doses (>20 mg)
- Subjective tolerance or diminishing acute effects after 2–4 weeks of continuous daily use
- Insomnia and vivid dreams with afternoon or evening dosing
- Anxiety or irritability in some users, especially when stacked with stimulants
- Highly variable individual response: some users report no noticeable effect
Science and community converge on 10–30 mg/day range, 8-week cycling protocol, morning dosing, and choline co-supplementation. Community anecdotally confirms the BDNF/NGF gradual neuroplasticity timeline described in clinical literature. Primary divergence: community reports subjective tolerance in some users after 3–4 weeks while clinical trials did not document pharmacological tolerance; community increasingly prefers sublingual/intranasal while trials used oral only.
Omberacetam (Noopept) Dosage Guide
| Level | Dose | Frequency |
|---|---|---|
| Beginner | 10 mg | Daily |
| Moderate | 10 mg | 3x Daily |
| Aggressive | 10 mg | 3x Daily |
No reconstitution needed. Omberacetam comes as tablets (Generium brand, 10 mg) or research powder. If you're using powder, you need a milligram-accurate scale (0.001 g precision). Standard kitchen scales can't resolve 10 mg doses.
The choline pairing isn't optional. Alpha-GPC 300 mg or CDP-choline 250 mg daily, starting the same day as omberacetam. This is the single most validated piece of community protocol wisdom for any nootropic.
Some research-grade capsules contain 30 mg each. That's the entire Russian daily maximum in one capsule, three times the standard single dose. If you're using these, you need to open the capsule and weigh out 10 mg. Don't take a full capsule as your dose.
Sublingual onset runs about 5 minutes versus 15 minutes oral. The practical difference in total duration is modest because CPG (the metabolite doing most of the work) lasts about seven hours either way. Sublingual is useful for pre-task acute effects; oral is fine for baseline cognitive support.
Genuine Russian Generium-brand pharmaceutical tablets are also available as gray-market imports. These are GMP-manufactured with accurate 10 mg dosing per tablet. US research powder varies in quality. A Certificate of Analysis is the only record of what a batch contains.
Cycling Protocol
Russian clinical protocols use 56-day (8-week) treatment courses at 20 mg/day. A 4-week washout period is recommended between cycles. Chronic administration does not appear to cause tolerance: BDNF and NGF upregulation actually increases with sustained use. Some users run shorter 4-week cycles with 2-week breaks.
The 8-week on / 4-week off cycle is derived directly from Russian clinical trial design (56-day treatment courses per Generium prescribing information), not from documented receptor desensitization, antibody formation, or hormonal axis effects. Animal and clinical data show BDNF/NGF upregulation does not diminish with continued use; true pharmacological tolerance is unlikely. Cycling is a precautionary convention based on trial methodology, designed to accommodate the minority of users who report subjective diminishing acute effects after 3–4 weeks of daily use.
- Subjective diminishing acute cognitive clarity after 3–4 weeks of continuous daily use (likely not true pharmacological tolerance: BDNF/NGF still upregulating per clinical data)
- Persistent insomnia despite morning-only dosing (indicates sensitization to excitatory component)
- Mood dysregulation, anxiety, or irritability that does not resolve with dose reduction (emerging adverse effect: discontinue, not a cycling signal)
- Headaches that do not resolve with adequate choline supplementation (reassess dose level or formulation quality)
Or use the universal Peptide Calculator for any peptide.
Omberacetam (Noopept) Protocols by Goal
Expected: Improved memory consolidation, reduced brain fog, mild anxiolytic effect. Most users notice subtle cognitive improvements within 1–2 weeks; full effects by weeks 4–8 per clinical trial timeline.
Monitor: Monitor for headaches (add choline if present), insomnia (shift dose earlier if occurring), irritability. Discontinue if psychiatric symptoms emerge.
How to Use Omberacetam (Noopept)
- 1Step 1
Choose your form: Generium 10 mg tablets (preferred for dose accuracy), research powder with a milligram scale, or research capsules (note the 30 mg capsule warning above).
- 2Step 2
Take 10 mg orally or sublingually in the morning, on an empty stomach or after a light meal. For sublingual, dissolve the tablet under your tongue for about 60 seconds. Onset is roughly 5 minutes sublingual, 15 minutes oral.
- 3Take your choline supplement at the same time
Alpha-GPC 300 mg or CDP-choline 250 mg, once daily.
- 4Step 4
If moving to the standard Russian clinical dose (intermediate protocol), add a second 10 mg dose at midday and a third in early afternoon. Never exceed 10 mg per individual dose or 30 mg per day total. At this frequency, increase choline to Alpha-GPC 300 to 600 mg or CDP-choline 500 mg daily.
- 5Step 5
Keep your last dose before 2 PM to avoid sleep disruption.
- 6Run the cycle for 56 days (8 weeks)
Then take a 4-week break before starting again. Up to three cycles per year follows Russian clinical practice.
- 7Step 7
Store tablets at room temperature (15 to 25 degrees Celsius) in a dry place away from direct light. No refrigeration needed.
Alternative Routes
10–30 mg/day; Tmax ~15 min; bioavailability of parent compound ~7–10% (oral first-pass) but CNS delivery is high due to lipophilicity and BBB penetration. Active metabolite CPG (t½ ~7h) provides sustained effect.
Russian Generium 10 mg tablets designed for this route: most clinically validated delivery method. Most convenient and accurate dosing for pharmaceutical tablets.
Same dose as oral (10–30 mg/day); Tmax ~5 min vs ~15 min oral; faster peak CNS delivery. Practical difference in total duration is modest since CPG metabolite (t½ ~7h) dominates sustained effect regardless of delivery route.
Tablet dissolved under tongue ~60 seconds, or powder in solution held sublingually. Faster onset appreciated by users seeking acute pre-task cognitive effect. No published human pharmacokinetic comparison of sublingual vs. oral routes for omberacetam specifically.
Community doses typically 1–10 mg intranasally; onset ~1–5 min; bypasses first-pass liver metabolism more completely than oral. Community reports heightened potency per mg vs. oral: some users use 5–10 mg intranasally where they would use 10 mg orally.
No published human pharmacokinetic data for intranasal omberacetam. Growing community preference for intranasal delivery as part of the full "Russian triple" stack (Semax + Selank + Noopept: all three dosed intranasally). Not pharmaceutical-grade.
Omberacetam (Noopept) Stacking Protocols
Works With
Mandatory choline co-supplementation to prevent cholinergic-depletion headaches. Omberacetam upregulates acetylcholine receptor activity, depleting choline reserves without supplementation. The #1 community-validated pairing: most headaches resolve within 24–48 hours of adding choline.
Alpha-GPC 300 mg once daily with first omberacetam dose; or CDP-choline 250 mg once daily
Complementary anxiolytic neuropeptide. Omberacetam provides glutamatergic cognitive enhancement; Selank modulates GABA-A and reduces HPA stress response. Separate mechanisms: additive, not redundant.
Selank 250–500 mcg intranasal + Omberacetam 10 mg oral, each morning
Complementary BDNF upregulator via ACTH4-7 mechanism; omberacetam via CPG/AMPA/NMDA pathway. Basis of the "Russian triple" (Semax + Selank + Noopept). Animal data supports complementary rather than redundant NMDA glycine-site modulation when combined.
Semax 200–500 mcg intranasal + Omberacetam 10 mg oral, morning
More potent, longer-acting Semax variant preferred by some users for the Noopept stack due to extended duration of action. Mechanistic rationale same as Semax.
NA-Semax Amidate 100–200 mcg intranasal + Omberacetam 10 mg oral, once daily
Avoid
Redundant glutamatergic mechanism. Co-use increases headache, irritability, and insomnia load without clear additive cognitive benefit at standard doses.
Additive cholinergic potentiation risks excessive acetylcholine activity: GI distress, bradycardia, overstimulation. Mechanism directly conflicts with omberacetam-driven cholinergic demand.
Do not combineAdditive excitatory effects increase insomnia, anxiety, and irritability risk. Community reports mood dysregulation with this combination, particularly in anxiety-prone users.
Counteracts neuroprotective CNS effects; conflicting CNS states (glutamatergic excitation vs. GABA/NMDA depression from alcohol) may worsen cognition and mood.
Estimated Cost
Pricing updated 2026-04-09
Omberacetam (Noopept) Side Effects
Psychiatric adverse effects deserve attention first. A case series (PMC4756795) documented four patients who developed new-onset anxiety disorder or mania attributed to omberacetam. That number is small, but the severity is real. Anyone with personal or family psychiatric history should approach this compound cautiously and monitor mood weekly.
Headache is the most common complaint, and it's almost entirely preventable. Omberacetam upregulates acetylcholine receptor activity, which depletes choline stores. Without supplemental Alpha-GPC (300 mg) or CDP-choline (250 mg), headaches typically appear within one to two hours of dosing. The community calls this predictable. Add choline on day one; don't wait for the headache.
Paradoxical brain fog at higher single doses is a well-documented finding. Taking 20 mg or more in a single dose can produce the exact cognitive impairment you're trying to fix. The pharmacology supports this; NMDA modulation has an inverted-U dose-response curve. If you experience mental haziness, drop back to 10 mg. More is genuinely not better with this compound.
Insomnia and vivid dreams show up when dosing runs past early afternoon. CPG has a seven-hour half-life, so a 2 PM dose is still active at 9 PM. Sublingual delivery in the afternoon is particularly disruptive to sleep because onset is faster and peak CNS levels run higher.
Irritability and restlessness occur in a subset of users, especially when stacking with stimulants like modafinil or high-dose caffeine. Dropping the stimulant usually resolves it.
Occasional GI discomfort has been reported but rarely leads to discontinuation. Rare blood pressure elevation warrants monitoring in anyone with borderline or uncontrolled hypertension. The Russian prescribing information lists this.
The LD50 in rats exceeds 2,000 mg/kg oral, which is roughly 100 times the therapeutic dose. Acute toxicity risk at standard doses is low.
Contraindications: pregnancy or breastfeeding (no safety data), known hypersensitivity to racetam-class compounds, severe hepatic impairment, severe renal impairment, children under 18, and uncontrolled hypertension.
When to stop and seek medical attention: new-onset anxiety that doesn't resolve within a few days of dose reduction, any hypomanic or manic symptoms, persistent insomnia despite morning-only dosing, or headaches that don't respond to choline supplementation.
Common Issues & Solutions
Headache within 1–2 hours of dosing: almost always choline deficiency: add Alpha-GPC 300 mg or CDP-choline 250 mg daily; headaches typically resolve within 24–48 hours. This is the #1 fixable complaint.
Paradoxical brain fog or confusion at higher single doses (>15–20 mg): reduce to 10 mg and do not titrate above 10 mg per dose: more is not better with omberacetam. A well-documented community and pharmacological finding.
Diminishing acute cognitive effects after 3–4 weeks of continuous daily use: implement 5-day-on/2-day-off micro-cycling within the active phase, or shift from 3× daily to 1–2× daily; full 4-week washout restores response for the next cycle.
Insomnia or vivid dreams: ensure last dose is no later than 1–2 PM; if persisting, shift to morning-only single dose. Sublingual delivery in the afternoon is particularly likely to cause sleep disruption.
Anxiety, irritability, or mood disturbance: reduce dose to 10 mg once daily and remove all stimulant co-administration; if psychiatric symptoms persist or escalate (anxiety disorder, hypomania, mania), discontinue immediately: 4 documented cases in PMC4756795.
Ask AI about this page
Ask AI for a second opinion on Omberacetam (Noopept) dosing and side effects
Contraindications
- Pregnancy or breastfeeding: no safety data available
- Known hypersensitivity to omberacetam or racetam-class compounds
- Severe hepatic impairment: metabolized via liver esterases
- Severe renal impairment: insufficient safety data
- Children under 18: not studied in pediatric populations
- Uncontrolled hypertension: rare reports of blood pressure elevation
Drug Interactions
- Cholinesterase inhibitors (donepezil, galantamine, rivastigmine): may potentiate cholinergic effects; increased risk of GI side effects and excessive acetylcholine activity
- Glutamatergic drugs (memantine, amantadine): additive effects on NMDA receptor modulation; use with caution
- Anticoagulants (warfarin): omberacetam may have mild antithrombotic properties; monitor INR if co-administered
- CNS stimulants (modafinil, amphetamines): potential for additive excitatory effects; may increase risk of insomnia or irritability
- Alcohol: not recommended; may counteract neuroprotective effects and increase CNS depression
- Other racetams (piracetam, aniracetam): redundant mechanism; co-use offers unclear benefit and increases side effect risk
- Benzodiazepines: omberacetam has mild anxiolytic properties that may alter sedation thresholds
Product Quality
Omberacetam is sold as pharmaceutical-grade Russian tablets (Generium brand, imported: GMP-manufactured, 10 mg tablets) and as unregulated US research-grade powder/capsules. Research powder requires milligram-accurate scales for precise 10 mg doses. Some research-grade capsules are 30 mg each: a full capsule equals the Russian daily maximum in a single dose, creating significant overdose risk if used as directed for "one capsule."
- Prefer genuine Russian Generium-brand pharmaceutical 10 mg tablets: highest dose accuracy and purity confidence for a compound where 10 mg is the standard unit.
- If using research powder, use a milligram-accurate scale (0.001 g precision): 10 mg doses require precision beyond a standard kitchen scale.
- Research-grade capsules sold at 30 mg each: do not take a full capsule as a single dose; 30 mg equals the Russian daily maximum in one administration and is 3× the standard dose.
- Pre-made nasal sprays (1 mg/spray, 100-spray bottle) offer dose-accurate delivery without powder-weighing errors: verify batch Certificate of Analysis before use.
- Without a third-party CoA, dose and purity are unverified; oral bioavailability of the parent compound is ~7–10%, making dose accuracy important for consistent CNS exposure.
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Blood pressure | Baseline and at weeks 2 and 8 | Systolic <140 mmHg, diastolic <90 mmHg |
| Mood and psychiatric symptom self-assessment | Weekly during first 4 weeks; biweekly weeks 4–8 | No new-onset anxiety disorder, hypomania, or manic symptoms |
| Sleep quality (subjective log) | Daily during first 2 weeks; weekly thereafter | Not listed |
| Cognitive performance (subjective or standardized) | Baseline, week 4, week 8, and 2 weeks post-cycle | Not listed |
Rare reports of blood pressure elevation; particularly relevant in individuals with borderline or uncontrolled hypertension (a listed contraindication).
PMC4756795 case series documented 4 cases of new-onset psychiatric adverse effects (anxiety disorder and mania) attributed to omberacetam. Active monitoring required, especially in individuals with personal or family psychiatric history.
Insomnia is a common side effect with afternoon or evening dosing. Sleep disruption compounds cognitive impairment and reduces therapeutic benefit.
Tracks therapeutic response and informs cycling decisions. Distinguishes genuine benefit from perceived effect.
Omberacetam (Noopept) Before and After
Some users report improved mental clarity and focus within the first dose due to rapid BBB penetration. Subtle improvements in alertness and verbal fluency. Effects may feel mild compared to stimulants: omberacetam works through gradual neurotrophin upregulation.
Memory recall and learning speed begin to improve. Anxiolytic effects emerge with reduced emotional reactivity to stress. BDNF and NGF upregulation is underway in the hippocampus.
Peak nootropic effects develop: improved working memory, faster information processing, and better attention span. Dream vividness and sleep quality may increase. Clinical studies show measurable improvement in Mini-Mental State scores by this point.
Full therapeutic benefit. Sustained improvements in cognition, emotional stability, and neuroprotection. BDNF and NGF expression continues to increase with chronic dosing rather than diminishing: no tolerance develops.
Cognitive benefits may persist for several weeks after discontinuation due to structural neuroplastic changes driven by BDNF and NGF. Gradual return to baseline over 2-4 weeks. Cycle can be repeated after a 4-week break.
What to Expect
Days 1 to 3 (Acute onset): The parent compound crosses the blood-brain barrier within minutes of oral or sublingual dosing. CPG metabolite (half-life around 7 hours) starts accumulating with repeated doses. Many users notice improved mental clarity and verbal fluency after the first sublingual dose. Tmax runs about 5 minutes sublingual, 15 minutes oral. Some of this early response may carry a placebo component. Headache within 1 to 2 hours signals choline depletion; add Alpha-GPC immediately. Mild irritability or vivid dreams the first night are common.
Days 4 to 14 (Early neuroplastic build): BDNF and NGF upregulation is progressing in the hippocampus and cortex. Anxiolytic effects become more noticeable as inhibitory neurotransmission adjusts. Memory recall and learning speed pick up, and users studying for exams report the most obvious changes in this window. Headaches should resolve if choline supplementation started on time. Watch for insomnia if any dose lands past 2 PM.
Weeks 2 to 4 (Peak acute cognitive effects): Clinical trials showed measurable MMSE improvement by day 28 in mild cognitive disorder patients. Working memory, information processing, and attention span hit their most noticeably improved levels. AMPA/NMDA receptor modulation is fully established. HIF-1 alpha neuroprotective signaling is active. This is the window where most users describe the strongest cognitive gains.
Weeks 4 to 8 (Full therapeutic and neuroprotective phase): BDNF and NGF expression continues increasing with sustained dosing. No pharmacological tolerance was documented through day 56 in Russian clinical trials. Experienced users describe a "quieter" but durable improvement, less acute than the early weeks but measurable in baseline function and emotional stability. Side effects are generally stable if choline is maintained and dosing stays before 2 PM.
Weeks 9 to 12 (Washout): Structural neuroplastic changes driven by BDNF and NGF persist after discontinuation. Gradual return to pre-cycle baseline over 2 to 4 weeks as neurotrophin levels normalize. A notable subset of users report that their acute response intensity is stronger when restarting after a full 4-week washout. The cycle can repeat after the break, up to three times per year.
Detailed Timeline: Science vs Community
Rapid BBB penetration after oral/sublingual dosing. CPG metabolite (t½ ~7h) begins accumulating with repeated dosing. BDNF/NGF upregulation underway in hippocampus but not yet clinically measurable. Tmax ~5 min sublingual, ~15 min oral.
Many users notice improved mental clarity, verbal fluency, and focus within the first dose (sublingual). A "cleaner" quality of thought is commonly described. Acute effects in this window may have a placebo component.
BDNF and NGF upregulation progressing in hippocampus and cortex. Anxiolytic effects emerge via modulation of inhibitory neurotransmission. Memory encoding measurably improving per animal model timelines.
Memory recall and learning speed improving: particularly useful during study periods. Anxiolytic effect becomes more noticeable. Vivid dreams continue for some users.
Clinical trials show measurable MMSE improvement by day 28 in mild cognitive disorder patients. Full AMPA/NMDA receptor modulation established. HIF-1α neuroprotective signaling active.
Working memory, information processing speed, and attention span peak. Many users describe this as the most noticeably enhanced cognitive window of the cycle.
BDNF/NGF expression continues to increase with sustained dosing: no pharmacological tolerance documented in Russian clinical trials through day 56.
Experienced users describe a "quieter" but durable cognitive improvement: less acute clarity than early weeks, but measurable improvement in baseline function and emotional stability.
Structural neuroplastic changes driven by BDNF/NGF persist after discontinuation. Gradual return to pre-cycle baseline over 2–4 weeks as neurotrophin levels normalize.
Many users report cognitive benefits persist for 2–4 weeks post-cycle. A notable subset reports enhanced acute response intensity when restarting after a full 4-week washout.
Pharmacokinetics
Source: Plasma t½ ~20 min in humans; active metabolite cycloprolylglycine (CPG) has a longer effective duration. Rat pharmacokinetics show t½ ~0.38 h (Boiko et al. 2000 PMID 10977920; Boiko et al. 2018 PMID 30378564)
Pharmacokinetics: Active Dose Over Time
t½ = ~15-20 min (plasma); active metabolite CPG persists longerDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Is Omberacetam (Noopept) Legal?
Omberacetam holds market authorization in Russia through Generium Pharmaceutical as a prescription nootropic for mild cognitive disorders of vascular and traumatic origin. The approved regimen is 10 mg up to three times daily for 56-day courses.
No FDA approval exists for any indication. The FDA has issued an import alert treating omberacetam (Noopept) as an unapproved drug, which means US customs can seize imported shipments. It is not a scheduled substance under the Controlled Substances Act. Possession is legal in the US, but it cannot be sold as a dietary supplement or drug.
Omberacetam powder and capsules are sold online labeled "for research purposes only." Genuine Russian pharmaceutical tablets also circulate as imports, which is a gray-market pathway.
Athletes should verify WADA status. Nootropics are not specifically listed on the WADA prohibited list, but novel psychoactive substances fall under a monitored category. Military personnel on expanded drug panels should confirm clearance with their command.
This content is for educational and informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any compound.
Evidence grade: Approved outside the US (Peptide Evidence Gap, October 2026)
Who Should Consider Omberacetam (Noopept)
- Adults with mild cognitive disorders of vascular or traumatic origin
- Individuals seeking memory and focus enhancement for academic or professional demands
- Older adults experiencing age-related cognitive decline
- People recovering from traumatic brain injury or concussion
- Those looking for a non-stimulant nootropic without addiction potential
- Users interested in long-term neuroprotection and neuroplasticity support
Related Peptides
What Changed for Omberacetam (Noopept)
Peptide Schedule Research TeamReviewed Apr 7, 202613 Citations
References
- [1]Comparative studies of Noopept and piracetam in patients with mild cognitive disorders (Neznamov & Teleshova 2009) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Noopept stimulates the expression of NGF and BDNF in rat hippocampus (Ostrovskaya et al. 2008) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]GVS-111 prevents oxidative damage and apoptosis in normal and Down syndrome human cortical neurons (Pelsman et al. 2003) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Anti-inflammatory properties of noopept (Alekseeva et al. 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Neuroprotective effect of noopept on AD-related cellular model: attenuation of apoptosis and tau hyperphosphorylation (Ostrovskaya et al. 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Pharmacokinetics of noopept and its active metabolite cycloprolylglycine in rats (Boiko et al. 2018) (opens in a new tab)PubMed 30378564PubMed
- Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration (Boiko et al. 2000) (opens in a new tab)PubMed 10977920PubMed
- Molecular mechanism underlying the action of substituted Pro-Gly dipeptide Noopept (Gudasheva et al. 2016) (opens in a new tab)PubMed 27099787Review
- Proline-containing dipeptide GVS-111 retains nootropic activity after oral administration (Ostrovskaya et al. 2001) (opens in a new tab)PubMed 11782792PubMed
- Noopept efficiency in experimental Alzheimer disease (Ostrovskaya et al. 2008) (opens in a new tab)PubMed 19145356PubMed
- Physicochemical and structural analysis of N-phenylacetyl-L-prolylglycine ethyl ester (Noopept) - An active pharmaceutical ingredient with nootropic activity (J Pharm Biomed Anal 2025) (opens in a new tab)PubMed 39298839PubMed
- PMC11712949 (PMC11712949) (opens in a new tab)PubMed
- PMC4756795 (PMC4756795) (opens in a new tab)PubMed
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Omberacetam (Noopept)?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 500+. Community mentions on Reddit: High (~500+ threads across r/Nootropics, r/nootropics). Open r/Nootropics (opens in a new tab).
200 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.